Reference Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Ref Type

PMID

Authors

D Hyman, S Kummar, A Farago, B Geoerger, M Mau-Sorensen, M Taylor, E Garralda, R Nagasubramanian, M Natheson, L Song, M Capra, M Jorgensen, A Ho, N Shukla, S Smith, X Huang, B Tuch, N Ku, TW. Laetsch, A Drilon, D Hong

Title

Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi)

Journal	Vol	Issue	Date	Pages	Journal Short Title
AACR Annual Meeting 2019 Online Proceedings

URL

https://www.abstractsonline.com/pp8/#!/6812/presentation/9845

Abstract Text

AACR Annual Meeting 2019, Abstract CT127

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 0 to 0 of 0 entries

Showing 0 to 0 of 0 entries

Filter rows:

Filter rows:

Showing 1 to 4 of 4 entries

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
NTRK1 fusion	Advanced Solid Tumor	predicted - sensitive	Selitrectinib	Phase I	Actionable	In a Phase I trial, Selitrectinib (LOXO-195) treatment resulted in an objective response rate of 34% (10/29) and stable disease in 31% (9/29) of adult and pediatric patients with advanced solid tumors harboring NTRK fusions and had progressed or were intolerant to prior Trk inhibitors (AACR Annual Meeting 2019, Abstract CT127; NCT03215511).	detail...
NTRK1 fusion NTRK1 mut	Advanced Solid Tumor	predicted - sensitive	Selitrectinib	Phase I	Actionable	In a Phase I trial, Selitrectinib (LOXO-195) treatment resulted in an objective response rate of 45% (9/20) and stable disease in 30% (6/20) of adult and pediatric patients with advanced solid tumors harboring a NTRK mutation associated with resistance to TRK inhibitors in the context of NTRK fusions, who had progressed or were intolerant to prior Trk inhibitors (AACR Annual Meeting 2019, Abstract CT127; NCT03215511).	detail...
NTRK2 fusion	Advanced Solid Tumor	predicted - sensitive	Selitrectinib	Phase I	Actionable	In a Phase I trial, Selitrectinib (LOXO-195) treatment resulted in an objective response rate of 34% (10/29) and stable disease in 31% (9/29) of adult and pediatric patients with advanced solid tumors harboring NTRK fusions and had progressed or were intolerant to prior Trk inhibitors (AACR Annual Meeting 2019, Abstract CT127; NCT03215511).	detail...
NTRK2 fusion NTRK2 mut	Advanced Solid Tumor	predicted - sensitive	Selitrectinib	Phase I	Actionable	In a Phase I trial, Selitrectinib (LOXO-195) treatment resulted in an objective response rate of 45% (9/20) and stable disease in 30% (6/20) of adult and pediatric patients with advanced solid tumors harboring a NTRK mutation associated with resistance to TRK inhibitors in the context of NTRK fusions, who had progressed or were intolerant to prior Trk inhibitors (AACR Annual Meeting 2019, Abstract CT127; NCT03215511).	detail...

Showing 1 to 4 of 4 entries

Filter rows: